ZYNLONTA® (loncastuximab tesirine-lpyl)
Relapsed/Refractory DLBCL
ApprovedCommercial
Key Facts
About ADC Therapeutics
ADC Therapeutics is a commercial-stage oncology company with a mission to transform cancer treatment through its proprietary ADC platform. Its key achievement is the FDA approval and commercialization of ZYNLONTA® for relapsed/refractory large B-cell lymphoma, establishing a revenue base. The company's strategy is to maximize ZYNLONTA's potential through label expansion while leveraging its differentiated linker/payload technology to advance a focused pipeline in high-need oncology indications.
View full company profileTherapeutic Areas
Other Relapsed/Refractory DLBCL Drugs
| Drug | Company | Phase |
|---|---|---|
| Maveropepimut-S (MVP-S) | BioVaxys | Phase 2B |
| Glofitamab | Roche | Approved |